JP2025506474A5 - - Google Patents
Info
- Publication number
- JP2025506474A5 JP2025506474A5 JP2024547308A JP2024547308A JP2025506474A5 JP 2025506474 A5 JP2025506474 A5 JP 2025506474A5 JP 2024547308 A JP2024547308 A JP 2024547308A JP 2024547308 A JP2024547308 A JP 2024547308A JP 2025506474 A5 JP2025506474 A5 JP 2025506474A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- disease
- pharmaceutical composition
- composition according
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022075603 | 2022-02-09 | ||
| CNPCT/CN2022/075603 | 2022-02-09 | ||
| PCT/CN2023/074938 WO2023151575A1 (en) | 2022-02-09 | 2023-02-08 | Heterocyclic glp-1 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506474A JP2025506474A (ja) | 2025-03-11 |
| JP2025506474A5 true JP2025506474A5 (https=) | 2026-02-17 |
Family
ID=87563628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547308A Pending JP2025506474A (ja) | 2022-02-09 | 2023-02-08 | ヘテロ環ｇｌｐ－１アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250145596A1 (https=) |
| EP (1) | EP4476213A1 (https=) |
| JP (1) | JP2025506474A (https=) |
| CN (1) | CN119072474A (https=) |
| WO (1) | WO2023151575A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250177362A1 (en) * | 2022-02-09 | 2025-06-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| CN113831337B (zh) * | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| JP2023537501A (ja) * | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
-
2023
- 2023-02-08 JP JP2024547308A patent/JP2025506474A/ja active Pending
- 2023-02-08 US US18/837,146 patent/US20250145596A1/en active Pending
- 2023-02-08 EP EP23752355.0A patent/EP4476213A1/en active Pending
- 2023-02-08 WO PCT/CN2023/074938 patent/WO2023151575A1/en not_active Ceased
- 2023-02-08 CN CN202380032342.9A patent/CN119072474A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025506474A5 (https=) | ||
| JP2025513071A5 (https=) | ||
| JP2025506473A5 (https=) | ||
| JP2023515404A5 (https=) | ||
| JP2023513272A5 (https=) | ||
| JP2025504508A5 (https=) | ||
| JP7358338B2 (ja) | 高血糖症の治療で使用するためのヘテロアリール置換されたベータ－ヒドロキシエチルアミン | |
| JP2023540609A5 (https=) | ||
| US12280023B2 (en) | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | |
| JP2025510741A5 (https=) | ||
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| JP2021091683A5 (https=) | ||
| TW200835482A (en) | GPCR agonists | |
| TW201038545A (en) | Bridged and fused antidiabetic compounds | |
| JP2023546125A5 (https=) | ||
| TWI864650B (zh) | Glp-1受體激動劑化合物之新穎鹽類、其製備方法以及包含其之醫藥組合物 | |
| CA3133768A1 (en) | Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia | |
| CN102803255A (zh) | 新的gpr119激动剂 | |
| TW200621220A (en) | Combination of organic compounds | |
| KR20240116482A (ko) | 과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태 | |
| JP2022525948A (ja) | 高血糖症の治療に有用なヘテロアリール（ヘテロシクリル）メタノール化合物 | |
| WO2016068453A1 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| US20100022554A1 (en) | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | |
| JP6782763B2 (ja) | 新規のピリジニウム化合物 | |
| US10428055B2 (en) | Substituted piperidines having GPR119 agonistic activity |